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Background: The relationship between progression of Alzheimer’s disease and depression 
and its underlying mechanisms has scarcely been studied. 
Methods: A sample of 282 outpatients with Alzheimer’s disease (AD; 105 with amnestic AD 
and 177 with Alzheimer’s dementia) from Norway were followed up for an average of two 
years. Assessment included Cornell Scale for Depression in Dementia and Clinical Dementia 
Rating Scale (CDR) at baseline and follow-up to examine the relationship between AD and 
depression. Additionally, MRI of the brain, CSF dementia biomarkers and APOE status were 
assessed at baseline. Progression of dementia was defined as the difference between CDR 
sum of boxes at follow-up and baseline (CDR-SB change). Trajectories of depressive 
symptoms on the Cornell Scale were identified using growth mixture modeling. Differences 
between the trajectories in regard to patients’ characteristics were investigated.  
Results: Three distinct trajectories of depressive symptoms were identified: 231 (82.8%) of 
the patients had stable low-average scores on the Cornell Scale (Class 1); 11 (3.9%) had high 
and decreasing scores (Class 2); and 37 (13.3%) had moderate and increasing scores (Class 
3). All classes had average probabilities over 80%, and confidence intervals were non-
overlapping. The only significant characteristic associated with membership in class 3 was 
CDR-SB change.  
Limitations: Not all patients screened for participation were included in the study, but the 
included and non-included patients did not differ significantly. Some patients with amnestic 
MCI might have been misdiagnosed.   
Conclusion: A more rapid progression of dementia was found in a group of patients with 
increasing depressive symptoms.  
 








The number of individuals with Alzheimer’s disease (AD) is increasing worldwide. In 2015, 
46.8 million people were identified as having AD, and it is estimated that 131.5 million will 
have the disease by 2050 (Alzheimer's disease international, 2015). A curative treatment for 
AD is still lacking. Therefore, efforts are being made to develop strategies to prevent the 
disease or to delay its progression. Several modifiable risk factors such as depression, diabetes 
and hypertension have been reported for AD dementia (Deckers et al., 2015, Kivipelto et al., 
2006, Norton et al., 2014, Ngandu et al., 2015).  
The literature regarding factors influencing the progression of AD is scarce. The identification 
of such factors, especially potentially modifiable factors, would be of crucial importance. The 
treatment of such conditions may be seen as a form of secondary prevention by slowing the 
progression of the disease and diminishing the negative consequences of AD. In this paper, 
we will focus on depression and its relationship to the progression of AD. 
The relationship between depression and dementia in AD is complex. Depression has been 
reported as a risk factor for all types of dementia, including AD (Saczynski et al., 2010, Byers 
and Yaffe, 2011, Ownby et al., 2006, Diniz et al., 2013, Deckers et al., 2015). In addition, 
several authors have pointed to the potential of preventing dementia by treating depression 
(Lyketsos et al., 2011, Kessing, 2012). Depression can be a prodromal symptom of dementia, 
especially when depression has its onset late in life and appears close to the onset of dementia 
(Li et al., 2011, Bennett and Thomas, 2014, Masters et al., 2015). It is also well known that 
depression can be a consequence of dementia (Lyketsos and Olin, 2002, Olin et al., 2002, 
Barca et al., 2010).  
The findings in regard to whether depression accelerates the progression of AD are 




of dementia among patients with AD (Leoutsakos et al., 2015), whereas other studies reported 
the opposite (Rapp et al., 2011, Wilson et al., 2002). However, pathophysiological 
mechanisms underlying depressive symptoms in AD and their roles in the progression of the 
disease have not yet been investigated.  
Depression and AD may have common etiological mechanisms. Depression may cause 
increased circulation of glucocorticoids, which, in turn, could lead to hippocampal atrophy 
(Byers and Yaffe, 2011). One study reported that patients with depression in AD had more 
medial temporal lobe atrophy (MTA) than patients with AD without depression (Dhikav et al., 
2014), and a post-mortem study revealed that AD patients with a history of depression had 
more neuritic plaques and neurofibrillary tangles in the hippocampus than those without a 
history of depression (Rapp et al., 2006). Another similarity is that cardiovascular diseases are 
risk factors for both depression and AD (Almeida et al., 2007, Kivipelto et al., 2006). 
Moreover, neuroinflammation has been reported in both depression and dementia, with 
increased levels of similar pro-inflammatory cytokines (Hong and Kim, 2016). Therefore, 
depression could pose an additive effect in AD. Indeed, it has been shown that depression 
(Modrego and Ferrandez, 2004) and, especially, increasing depressive symptoms over time 
(Kaup et al., 2016) are risk factors for all-cause dementia. However, whether increasing 
depressive symptoms over time in AD accelerate cognitive decline or the progression of 
dementia has not yet been investigated.  
This is an exploratory study that aims to investigate the different trajectories of depressive 
symptoms among patients with AD and the relationship between the progression of AD and 






The Prognosis of Alzheimer’s disease and Resource use (PADR) study is a longitudinal, 
observational study among Norwegian patients from two memory clinics and one geriatric 
outpatient unit, with one assessment at the time of the patients’ first visit to the clinics and one 
follow-up assessment after 16–37 months. Inclusion criteria were: having a diagnosis of MCI 
or dementia, having the capacity to provide consent at baseline, having an available proxy, 
being fluent in the Norwegian language, living in proximity to the center (close enough to be 
reassessed) and having no serious comorbid diseases at baseline.  
Of 555 patients screened, 198 were not included at follow-up due to various reasons, resulting 
in 357 patients being assessed after an average of two years. Patients with diagnoses other 
than AD, such as non-amnestic mild cognitive impairment and other types of dementia 
(N=75) were excluded from the present study, resulting in 282 patients with Alzheimer’s 
disease: 177 with dementia due to AD and 105 with prodromal AD defined as amnestic MCI, 
(see “Diagnoses” for details). Patients who completed follow-up had completed more years of 
education compared to those who did not complete follow-up. Otherwise, there were no 
differences regarding age, gender, Cornell score, CDR sum of boxes, and MMSE score.  
Figure 1 here 
Assessments 
The baseline assessments of the patients were performed by physicians at the outpatient 
clinics and included a clinical history from patients and their caregivers, neuropsychological 
tests, physical and cognitive examinations, blood analyses (including analysis of APO E 
status among 252 patients) and, usually, structural brain imaging with MRI or CT. In some 
cases, SPECT and PET were also performed. Cerebrospinal fluid (CSF) was drawn from 110 
of the 282 patients for the analyses of amyloid-β (Aβ), total tau (T-tau) and phospho tau (P-




daily living and neuropsychiatric symptoms including depression. The follow-up assessment 
was conducted by research physicians using a protocol similar to that at baseline. 
Additionally, saliva was collected, three times during the same day.  
The demographic characteristics included were age, gender and level of education. 
Cardiovascular diseases were dichotomized based on the history of cardiovascular disease at 
baseline. Anatomical Therapeutic Chemical (ATC) codes were registered for all drugs. 
Antidepressants were identified by the pharmacological subgroup N06A and dichotomized for 
any antidepressant used at baseline. 
The Cornell Scale for Depression in Dementia (CSDD) was used to rate the severity of 
depressive symptoms (Alexopoulos et al., 1988). The scale has been validated in Norwegian 
memory clinics, and a cut-off ≥6 was found for depression (Knapskog et al., 2011). Each of 
the 19 items is rated from 0 (no symptom) to 2 (severe symptom), giving a sum score of 0–38, 
with higher scores indicating more severe depression. Several items in the Cornell Scale were 
scored as “not possible to evaluate”. Such items would affect the sum score, making it 
artificially low. Therefore, the average score was used as a continuous variable at baseline and 
at follow-up.  
The Physical Self-Maintenance Scale was used to assess the patients’ abilities to perform 
personal activities of daily living (PADL). This scale has six items, and each item can be 
scored between 1 and 5. The Instrumental Activities of Daily Living Scale (IADL) was used 
to evaluate instrumental activities of daily living. This scale has eight items, and each item 
can be scored between 0 and 3–5; a higher score denotes greater impairment (Lawton and 
Brody, 1969). Both scales were summarized to evaluate activities of daily living (ADL) as 




The Mini-Mental State Examination (MMSE) was applied to rate global cognitive 
functioning. The score on the MMSE varies between 0 and 30; a higher score denotes better 
cognition (Folstein et al., 1975).  
The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) 10-word delayed 
recall test was performed, with scores between 0 and 10; a higher score denotes better delayed 
recall (Fillenbaum, 2008). 
We used the Clinical Dementia Rating Scale (CDR) (Hughes et al., 1982) to assess the 
severity of dementia. This instrument includes six domains: memory, orientation, judgement 
and problem solving, community affairs, home and hobbies, and personal care. We calculated 
the CDR sum of boxes (CDR-SB), where 0 indicates no impairment and 18 the most severe 
impairment.  The CDR-SB has been proposed as the primary outcome measure for clinical 
trials in early AD (Cedarbaum et al., 2013). All study researchers underwent online training 
and fulfilled the requirements for certification. A difference between CDR-SB at follow-up 
and CDR-SB at baseline was used to assess progression.  
Magnetic resonance imaging (MRI) was evaluated visually for medial temporal lobe atrophy 
(MTA) according to the Scheltens’ Scale by an experienced neuroradiologist. This scale 
varies between 0 and 4, where a higher score indicates more atrophy (Scheltens et al., 1992). 
We added the scores for the right and left sides and used this measurement as one continuous 
variable. MRI was also evaluated regarding white matter hyperintensities (WMH) with the 
Fazekas Scale. This scale evaluates white matter lesions and the score varies between 0 and 3; 
higher scores indicate more hyperintensities in the white matter. It was also used as a 
continuous variable (Fazekas et al., 1987). At baseline, 242 MRIs were evaluated. However, 
17 of these were performed more than six months before or after the baseline evaluation and 




APOE typing was performed using the Illumina Infinium OmniExpress v1.1 chip at deCODE 
Genetics, Reykjavik, Iceland. APOE ε4 status was dichotomized according to the presence or 
absence of one or two APOE ε4 allele(s). Saliva was collected at three time points during the 
same day (morning, 7–9am; afternoon, 12–2pm; and evening, 9–11pm) according to 
recommended procedures using Salivette (Sarstedt®) and analyzed for concentration of 
cortisol using first-generation methodology. In the present study, the values for cortisol were 
used as a continuous variable. 
Diagnoses  
Dementia diagnoses were made by one or two experienced physicians (details in the next 
paragraph) according to the ICD-10 criteria for research. For dementia due to AD, we used 
the NINCDS-ADRDA criteria (McKhann et al., 1984). The Winblad criteria were used for 
MCI (Winblad et al., 2004). When diagnosing the patients at baseline, all available data from 
the first visit, such as anamnesis from both the patient and a caregiver, results from a 
neuropsychological test battery, physical examination, blood tests and results from 
supplementary examinations such as MRI of the brain, brain SPECT/PET and the CSF 
biomarkers Aβ, T-tau and P-tau, were used. Patients with amnestic MCI (aMCI), defined as 
MCI patients with memory complaints as expressed by the patient and/or caregiver and a 
score below -1.5 SD on at least one memory test, with no other obvious etiology for cognitive 
impairment, were regarded as Alzheimer’s disease patients. Additionally, CSF biomarkers 
and clinical MRI reports were used when sub-categorizing the MCI patients.  
In 51 patients randomly selected from baseline, an inter-rater reliability analysis between the 
diagnoses made by two of the doctors in the project (MLB and KP) was performed. The result 
showed acceptable inter-rater agreement for the MCI diagnosis (kappa=0.66) and for 




clinic, all AD patients were diagnosed by one skilled doctor. For all other patients (N=130), 
the diagnosis was discussed in consensus with a skilled professor (KE). Patients from the 
other two clinics were diagnosed by two doctors with significant amounts of experience in 
dementia work-up in consensus. At follow-up, all patients were diagnosed by two experienced 
doctors in consensus.  
Statistical analysis 
Missing values on PADL, IADL and Cornell items were imputed by drawing a random 
number from an empirical distribution generated for each relevant item. The imputation was 
performed only for patients with fewer than half of the values missing on the scale. 
Differences between groups were analyzed with Mann-Whitney or Kruskal-Wallis tests for 
continuous and χ2- test for categorical variables. A growth mixture model was estimated 
based on the mean Cornell score, with an attempt to identify unobserved classes of patients, 
each following a distinct trajectory. Due to still-missing values (“not possible to evaluate”) on 
several Cornell items after imputation, the mean score was used instead of the sum score. 
Missing values would produce artificially low sum scores, while this problem is avoided by 
averaging the scores of existing items. Akaike’s Information Criterion (AIC) was applied for 
identifying trajectories. In addition, the average class probabilities were expected to be larger 
than 0.7 and to have 95% confidence intervals (CI) for non-overlapping trajectories. To 
determine patient characteristics that could describe the trajectory classes, first, a number of 
bivariate analyses were carried out. Then the multivariate regression model with class 
membership as a dependent variable was estimated and reduced by applying AIC. All 






Ethical issues   
The study was approved by the Regional Committee of Medical Research Ethics of the South-
East Norway Regional Health Authority (REC South-East number 2011/531). All patients 
were informed and signed an informed consent. 
Results 
Three patients had missing on the Cornell Scale on both baseline and follow-up and had to be 
excluded from the analyses. Characteristics of the 279 patients and differences between the 
two AD groups (with and without dementia) are shown in Table 1. Patients with aMCI were 
younger, had higher levels of education, higher MMSE and lower CDR-SB, ADL, Cornell 
and MTA scores, as well as higher Aβ than those with AD. The prevalence of depression at 
baseline was 36.3% and 32.5% at follow-up, according to the Cornell Scale applying the 
Norwegian cut-off for memory clinics (score of 6 and above).  
Table 1 here 
Three distinct trajectories of depressive symptoms on the Cornell Scale were identified 
according to a growth mixture model (Figure 2). In all, 231 patients (82.8%) had stable low 
scores on the Cornell (Class 1); 11 patients (3.9%) had high and decreasing scores (Class 2); 
and 37 patients (13.3%) had moderate and increasing scores on the Cornell Scale (Class 3). 
All classes had average probabilities above 0.80 (Table 2) and confidence intervals were non-
overlapping, clearly indicating distinct groups of patients.  
Figure 2 here 




To explore how the patients of the different trajectories differed, we compared patient 
characteristics at baseline across classes of trajectories (Table 3). Compared to class 1, 
patients in class 2 had higher CDR-SB and used more antidepressants at baseline. Compared 
to class 1, patients in class 3 had lower Aβ, and a higher proportion used antidepressants at 
baseline; they also had a more rapid dementia progression according to CDR change. Class 2 
and class 3 had no statistically significant differences in any characteristic.  
Table 3 here 
Class 2 was, unfortunately, too small to be included in the multivariate analysis. Therefore, 
we continued the analyses comparing class 3 with class 1 using logistic regression. First, 
unadjusted analyses were performed with class 3 versus class 1 as the dependent variable, and 
characteristics described in Table 3 were used as independent variables. However, there were 
too few patients with CSF biomarkers and cortisol, so we had to exclude these variables from 
further analyses to avoid bias. Instead, we added diagnosis (aMCI vs. dementia) as an 
independent variable, since we had found that patients with aMCI had higher Aβ levels. Table 
4 shows the unadjusted odds ratios. The only significant characteristic that was associated 
with class membership in group 3 compared to class membership in group 1 in the 
multivariate model was the CDR change, indicating that the a more rapid progression as 
measured by CDR between baseline and follow-up was associated with increasing depressive 
symptoms as measured by the Cornell Scale.  
Table 4 here 
Discussion 
The main aim of the present study was to investigate the underlying trajectories of depressive 
symptoms among patients with AD. We found three distinct trajectories of depressive 




changes in the Cornell score; the second-largest class had moderate symptoms at baseline that 
increased; and the smallest class had severe symptoms at baseline that decreased.  
To the best of our knowledge, this is the first study that has investigated trajectories of 
depressive symptoms among patients with AD in a clinical sample. Two recently published 
studies have evaluated trajectories of depressive symptoms among community-dwelling older 
adults. One of these studies evaluated elderly persons without dementia according to the 
Center for Epidemiologic Studies Depression Scale Short Form with 10 items (CES-D) and 
found three trajectories, consistently minimal symptoms (62.0%), moderate and increasing 
symptoms over time (32.2%), and high and increasing symptoms over time (5.8%) (Kaup et 
al., 2016). Another study of elderly persons, including both persons with and without 
cognitive impairment, found five trajectories of depressive symptoms using the complete 
CES-D scale with 20 items: rarely depressed (60.5%); low-grade, decreasing symptoms 
(18.5%); low-grade, increasing symptoms (9.6%); moderate-grade symptoms (7.4%); and 
consistently higher-grade symptoms (4.0%) (Graziane et al., 2016). Our findings are in line 
with the trajectories found by Kaup et al., that is, the largest group with constantly minimal 
depressive symptoms, the second-largest with moderate and increasing symptoms, and a third 
group with more severe symptoms that increased over time. In contrast, we found a small 
group with severe depressive symptoms that decreased over time. The reduction of depressive 
symptoms could not be explained by increased use of antidepressants or by differences in 
APOE ε4 status between the classes of trajectories. We suggest that the use of various 
depression scales may explain the differences between studies. The population studies used 
the CES-D scale in two different forms. The present study used the CSDD, which was 
originally developed to measure depressive symptoms among patients with dementia but is 




Differences between groups were investigated. Patients in group 2, with decreasing depressive 
symptoms, had higher CDR-SB and used more often antidepressants at baseline compared to 
patients in group 1. This can be regarded as an indirect sign that antidepressants were 
effective. Patients in group 3, that had moderate depressive symptoms that increased, also 
used more often antidepressants compared to patients in group 1. This is surprising, especially 
due to the finding that antidepressants were associated with decreasing depressive symptoms 
among patients in group 2. However, patients in group 3 had lower levels of Amyloid β, 
which might indicate more brain pathology. It is known that antidepressants have poorer 
effect among patients with Alzheimer’s dementia than among elders without dementia (Bains 
et al., 2006, Thompson et al., 2007, Leong, 2014). However, there were no differences 
between group 2 and 3 regarding symptom severity of dementia as measured by the CDR-SB. 
Furthermore, only CDR-SB change was significant in the adjusted analyses. Therefore, we 
assume that the progression of dementia cannot be avoided in spite of antidepressant use. 
We found that greater progression of AD is associated with increasing depressive symptoms, 
adjusted for several factors, such as demographic characteristics, cardiovascular comorbidity, 
APOE ε4 status and MRI findings such as atrophy of medial temporal lobe according to 
Scheltens’ Scale and white matter hyperintensities according to Fazekas’ Scale, antidepressant 
use and dementia vs MCI diagnosis.  
Controversial findings have been reported in regard to whether depression accelerates the 
progression of AD. Several studies have found that depression accelerates dementia 
progression (Wilson et al., 2002, Rapp et al., 2011), but another study that adjusted the 
analyses for a number of factors did not (Leoutsakos et al., 2015). The study by Kaup et al. 
found that the high and increasing trajectory of depressive symptoms increased the risk of 
incident dementia compared to the consistently minimal trajectory adjusted for several 




(Kaup et al., 2016). Another previously mentioned study found an association between 
increasing depressive symptoms and poor cognition (Graziane et al., 2016). That study 
investigated associations between depression trajectories and trajectories of a number of 
cognitive domains and found that the low-grade increasing depression trajectory class, and not 
the high-grade class, was associated with persistently poor cognitive functioning, a finding 
different compared to the present study. Several mechanisms have been hypothesized for why 
depression would be associated with faster or greater progression of Alzheimer’s disease. 
First, it has been shown that chronic depression leads to hippocampal atrophy (Sheline et al., 
2003). Moreover, cardiovascular factors are risk factors for both depression (Almeida et al., 
2007) and dementia (Kivipelto et al., 2006), and it is possible that these factors would booster 
the progression of Alzheimer’s disease in patients with comorbid depression. We investigated 
differences between the trajectory classes with increasing depressive symptoms and with 
minimal depressive symptoms. For the reasons listed above, we would expect that the group 
with increasing depressive symptoms would have more medial temporal atrophy, more white 
matter hyperintensities and more cardiovascular diseases. However, this was not the case. One 
possible explanation for why we did not find such associations is that these patients had 
moderate depressive symptoms at baseline. It could be that they did not have these brain 
lesions as mentioned by other authors (Sheline et al., 2003) because they did not have severe 
enough depression to cause these alterations in the brain. It has been argued that one single 
measurement of depression is simply a snapshot and does not illustrate the whole process 
(Graziane et al., 2016). Some persons might be in a phase marked by the worsening of the 
depression and others in an ameliorating phase, as also shown by our results. Another 
possibility is that other brain regions might be involved in increasing depressive symptoms in 
our sample, such as the frontal lobe, as shown in another cohort (Soennesyn et al., 2012). 




present more Alzheimer’s pathology as measured by CSF markers (Auning et al., 2015, Diniz 
et al., 2014). 
Another possible explanation for our finding is that patients with faster dementia progression 
react with more depressive symptoms. There might be two mechanisms in this case: that 
faster progression leads to depression through biological or psychological mechanisms. Faster 
progression of dementia could lead to more depressive symptoms because of brain damages 
that could lead to organic depression through frontolimbic and frontostriatal pathways. 
Depression could also occur as a psychological reaction to greater impairments. It has been 
shown that awareness of the disease is associated with depression (Migliorelli et al., 1995). 
Finally, there is the possibility that depression may have caused cognitive impairment. 
This study has some limitations. First, we have not included all the patients screened for 
inclusion, but the patients included and not included did not differ significantly. Also, the 
sample size is small compared to large population cohorts. The external validity for patients 
with MCI and dementia in the community is also limited, since it is a selective sample from a 
memory clinic. Another limitation is that some patients might have been misdiagnosed. We 
wanted to include all the patients from the spectrum of Alzheimer’s disease (MCI and 
dementia stages), but some of the patients with MCI might have been classified with 
Alzheimer’s disease without having it. However, 67 (63.8%) patients with aMCI at baseline 
progressed to dementia after the period of two years. Another limitation is that, since it is an 
observational study rather than an intervention study, we are not able to assure that the 
improvement of depressive symptoms was due to antidepressant treatment. The strength of 
our study is that is has been conducted in a clinical setting using valid scales and advanced 





In conclusion, we have found three trajectories of depressive symptoms. To the best of our 
knowledge, this is the first study to investigate trajectories of depressive symptoms in a 
clinical sample. Our findings are comparable to trajectories of depressive symptoms found in 
population studies. We also found that more rapid progression in dementia is associated with 
the moderate and increasing depressive symptoms trajectory.  
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74.7 (7.6) 0.0021 
Women, n=282, n (%)  152 
(53.9) 
50 (47.6) 102 (57.6) 0.1032 
Education, years, n=282, mean (SD)  11.7 
(3.6) 
12.7 (3.5) 11.1 (3.5) <0.0011 
MMSE, n=280, mean (SD)  23.7 
(4.4) 
26.7 (2.5) 22.0 (4.3) <0.0011 
CDR-SB, n=282, mean (SD)  4.3 (2.8) 2.1 (1.3) 5.6 (2.5) <0.0011 
ADL, n=273, mean (SD)   18.4 
(5.6) 
15.8 (2.9) 20.2 (6.4) <0.0011 
Cornell score, n=259, median (range)  4.0 (0-
27) 
3.0 (0-18) 5.0 (0-27) 0.0081 
Cardiovascular diseases, n=282, yes (%) 173 
(61.3) 
60 (57.1) 113 (63.8) 0.2642 
APOE ε4 carrier, n=252, yes, n (%)  149 
(52.8) 
51 (55.4) 98 (61.3) 0.3662 
MTA, n=212, median (range) 4.0 (0-8) 3.0 (0-7) 4.0 (0-8) <0.0011 
WMH n=215, median (range) 2.0 (0-3) 2.0 (0-3) 2.0 (0-3) 0.2131 




518.9 (195.2) <0.0011 




689.5 (333.3) 0.2611 




86.3 (35.0) 0.1611 




18.0 (17.5) 0.1701 
Cortisol afternoon, n=187, mean (SD)  10.6 
(17.2) 
8.6 (8.3) 11.8 (21.2) 0.1121 
Cortisol evening, n=181, mean (SD)  8.1 
(22.4) 
6.4 (7.5) 9.3 (28.7) 0.8371 
Antidepressant, n=282, yes, n (%) 31 (11) 11 (10.5) 20 (11.3) 0.8612 

















Table 2. Trajectories analysis of depressive symptoms by the Cornell scale for depression 
Variable 
Class 1 (N=231) Class 2 (N=11) Class 3 (N=37) 





Intercept 0.23 (0.03) <0.001 1.48 (0.23) <0.001 0.10 (0.13) 0.421 
Time -0.04 (0.02) 0.039 -0.52 (0.13) <0.001 0.30 (0.09) 0.001 



































1 Kruskall-Wallis test 2 χ2-test 3 Mann-Whitney test 
 
Table 3. Unadjusted differences between trajectories groups 
 Class 1 Class 2 Class 3 p-
value 
C1 vs C2 C1 vs C3 C2 vs C3 
Age, n=279, mean (SD) 73.5 (8.7) 66.8 
(11.3) 
73.1 (7.9) 0.1471 0.0543 0.7033 0.1053 
Women, n=279, n (%) 125 (54.1) 7 (63.6) 18 (48.6) 0.6602 0.5352 0.5362 0.3822 
MMSE, n=277, mean (SD) 23.8 (4.4) 22.3 (6.3) 23.4 (3.8) 0.6131 0.5333 0.4173 0.8603 
CDR-SB, n=279, mean (SD) 4.2 (2.8) 6.0 (2.1) 4.5 (2.3) 0.0222 0.0102 0.2582 0.0562 
CDR change, n=279, mean (SD) 2.9 (3.4) 3.5 (3.9) 4.8 (4.2) 0.0201 0.4583 0.0063 0.4183 
ADL, n=257, mean (SD) 18.2 (5.7) 21.6 (4.2) 19.6 (5.5) 0.0661 0.0673 0.1143 0.3833 
Cardiovascular diseases, n=279, yes, n (%) 143 (61.9) 9 (81.8) 20 (54.1) 0.2462 0.1822 0.3642 0.0982 
Apo E ε4 carrier, n=249, yes, n (%) 122 (59.5) 5 (55.6) 20 (57.1) 0.9442 0.8132 0.7922 0.9322 
MTA, n=231, mean (SD) 3.7 (1.9) 4.9 (2.3) 3.7 (1.7) 0.3731 0.1723 0.7743 0.1863 
WMH, n= 240, mean (SD) 2.0 (0.9) 1.9 (0.8) 2.0 (0.9) 0.9641 0.7913 0.9493 0.8213 
Amyloid β, n=110, mean, (SD) 605 (257) 807 (0) 504 (307) 0.0491 0.2113 0.0333 0.2643 
Total tau, n=110, mean, (SD) 680 (325) 230 (0) 575 (278) 0.1741 0.1163 0.2993 0.1723 
Phospho tau, n=110, mean, (SD) 85.0 (34.0) 34.0 (0) 71.4 (25.0) 0.1141 0.1003 0.2003 0.1073 
Cortisol morning, n=180, mean (SD) 20.1 (28.5) 18.7 (9.9) 26.1 (31.5) 0.5101 0.6463 0.2773 0.8653 
Cortisol afternoon, n=184, mean (SD) 10.2 (17.8) 10.5 (4.8) 13.6 (15.3) 0.0941 0.1393 0.0903 1.0003 
Cortisol evening, n= 179, mean (SD) 7.2 (19.8) 9.6 (6.5) 16.8 (40.4) 0.0561 0.0773 0.0853 0.5513 





Table 4. Logistic regression for class membership in class 3 (moderate and increasing 
symptoms) with class 1 as reference. N=201 
Variable Bivariate models Multivariate model 
 OR (95% CI) p-value OR (95% CI) p-value 
Age 0.99 (0.94; 1.03) 0.523   
Gender 0.67 (0.31; 1.48) 0.323   
Education, years 1.04 (0.94; 1.16) 0.462   
MMSE sum 0.99 (0.91; 1.09) 0.904   
CDR change 1.14 (1.03; 1.25) 0.009 1.14 (1.03; 1.25) 0.009 
ADL sum 0.98 (0.87; 1.11) 0.767   
Cardiovascular diseases 0.26 (0.50; 1.38) 0.114   
APOE 4 carrier 1.07 (0.24; 4.66) 0.932   
MTA 0.68 (0.42; 1.12) 0.132   
WMH 1.01 (0.65; 1.57) 0.972   
Antidepressant (yes/no) 2.73 (0.96; 7.75) 0.059   
aMCI vs. dementia 2.22 (0.86; 5.73) 0.101   
 
 
